Dopamine antagonists for treatment resistance in autism spectrum disorders review and focus on BDNF stimulators loxapine and amitriptyline
Revision as of 06:46, 20 August 2022 by 187.21.138.9 (talk) (Created page with "== Target Article == Dopamine antagonists for treatment resistance in autism spectrum disorders review and focus on BDNF stimulators loxapine and amitriptyline; JA Hellings, LE Arnold, JC Han; 2017; doi_citing_unknown == Retraction == Effects of Thioridazine on the Intellectual Performance of Mentally Retarded Drug Responders and Nonresponders ; Stephen E Breuning Donald G Ferguson Neal A. Davidson; 03/01/1983 ; doi_cited_unknown == Citation piece == Note: Open to ap...")
Target Article[edit | edit source]
Dopamine antagonists for treatment resistance in autism spectrum disorders review and focus on BDNF stimulators loxapine and amitriptyline; JA Hellings, LE Arnold, JC Han; 2017; doi_citing_unknown
Retraction[edit | edit source]
Effects of Thioridazine on the Intellectual Performance of Mentally Retarded Drug Responders and Nonresponders ; Stephen E Breuning Donald G Ferguson Neal A. Davidson; 03/01/1983
- doi_cited_unknown
Citation piece[edit | edit source]
Note: Open to append information.